Silas Inman | Authors

Articles

Impressive Results Continue With Updated Data on bb21217 in Multiple Myeloma

December 11, 2019

In the phase I CRB-402 study, patients with heavily pretreated relapsed/refractory multiple myeloma and minimal residual disease negativity had very good partial responses to the anti-BCMA CAR T cell therapy bb21217, according to updated results presented at the 2019 American Society of Hematology Annual Meeting.

Navitoclax Shows Activity in Ruxolitinib-Resistant Patients With Myelofibrosis

December 10, 2019

Patients with primary or secondary myelofibrosis who developed resistance to ruxolitinib in the frontline setting, showed clinically meaningful spleen responses and improvements in symptoms with the addition of navitoclax to ruxolitinib, according to findings from a phase II study presented at the 2019 ASH Annual Meeting.

CC-486 Maintenance Extends OS in Older Patients With Acute Myeloid Leukemia

December 10, 2019

An extended media overall survival of 9.9 months was achieved with CC-486 maintenance treatment compared with placebo for older patients with acute myeloid leukemia in first remission, according to findings from the phase III QUAZAR AML-001 trial presented at the 2019 American Society of Hematology Annual Meeting.

FDA Submission for KTE-X19 Planned After High CR Rates Were Observed in MCL

December 10, 2019

Patients with relapsed/refractory mantle cell lymphoma experienced a 67% complete remission rate and an objective response rate of 93% after treatment with the anti-CD19 CAR T-cell therapy KTE-X19, according to findings from the phase II ZUMA-2 study presented at the 2019 American Society of Hematology ASH Annual Meeting.

Zanubrutinib Highly Effective in CLL/SLL, Despite Presence of High-Risk Cytogenetics

December 09, 2019

In the SEQUOIA trial, zanubrutinib, a Bruton’s tyrosine kinase inhibitor, showed continued high overall response rates for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, regardless of deletion 17p status, according to findings presented at the American Socitey of Hematology Annual Meeting and Exposition.

LOXO-305 Shows High Efficacy in Patient With Heavily Pretreated B-cell Malignancies

December 09, 2019

Treatment with LOXO-305 prompted responses from more than half of patients with heavily pretreated B-cell malignancies, including patients with resistance or intolerance to other BTK inhibitors or BCL2 inhibitors, according to findings from the phase I/II BRUIN trial presented at the 2019 American Society of Hematology Annual Meeting and Exposition.